How has the cc chemokine receptor type 5 market evolved, and where is it heading next?
The CC chemokine receptor type 5 market size has grown rapidly in recent years. It will grow from $1.4 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to government funding, R&D collaborations, public health campaigns, public-private partnerships, and the discovery of CCR5.
The CC chemokine receptor type 5 market size is expected to see rapid growth in the next few years. It will grow to $2.27 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to the prevalence of HIV or AIDS, healthcare infrastructure, economic incentives, increasing demand for healthcare, and economic growth. Major trends in the forecast period include expanding research on cancer treatment, development of combination therapies, development of pharmaceutical manufacturing, strategic collaborations and partnerships, and clinical trials expansion.
Get Your Free Sample of The Global CC Chemokine Receptor Type 5 Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18290&type=smp
What are the key drivers behind the rapid expansion of the cc chemokine receptor type 5 market?
The increasing prevalence of chronic diseases is expected to propel the growth of the CC chemokine receptor type 5 market going forward. Chronic diseases refers to long-term medical conditions, such as heart disease, diabetes, and arthritis, that progress slowly and often require ongoing management. The prevalence of chronic diseases is growing due to aging populations and increasing rates of lifestyle-related risk factors such as poor diet, physical inactivity, and obesity. CC Chemokine Receptor Type 5 (CCR5) is crucial in chronic diseases such as human immunodeficiency virus (HIV), as it acts as a coreceptor that allows the virus to enter and infect immune cells, playing a key role in the progression of the disease. For instance, in October 2023, according to the Joint United Nations Programme on HIV/AIDS, a Switzerland-based, comprehensive global program to prevent HIV infection, in 2021, around 38.7 million people were infected with HIV, which increased to 39.0 million people in 2022, with 1.3 million newly infected people in the year 2022. Therefore, the increasing prevalence of chronic diseases is driving the growth of the CC chemokine receptor type 5 market.
What is the segmentation for the cc chemokine receptor type 5 market?
The CC chemokine receptor type 5 market covered in this report is segmented –
1) By Type: BMS-813160, AG-1105, CCL-14, DS-001, Other Types
2) By Distribution Channel: Hospitals, Clinics, Online Pharmacies, Retail Pharmacies
3) By Application: Infectious Disease, Gastrointestinal, Immunology, Oncology, Other Applications
4) By End User: Research Institutes, Pharmaceutical Companies, Healthcare Facilities
Subsegments:
1) By BMS-813160: CCR5 Antagonist For HIV Treatment, CCR5 Antagonist For Inflammatory Diseases
2) By AG-1105: CCR5 Antagonist For Autoimmune Disorders, CCR5 Antagonist For Cancer Therapy
3) By CCL-14: Chemokine Ligand For Targeted Therapy, CCL-14 For Immune Modulation
4) By DS-001: CCR5 Inhibitor For Cancer Treatment, DS-001 For Inflammatory Disease Management
5) By Other Types: Novel CCR5 Antagonists, Dual-Target CCR5 Antagonists
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report
Who are the most influential companies in the cc chemokine receptor type 5 market?
Major companies operating in the cc chemokine receptor type 5 market are Pfizer Inc., Sorrento Therapeutics, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Avexa Limited, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical, Gilead Sciences Inc., Vertex Pharmaceuticals, Ono Pharmaceutical Co Ltd, Abcam Limited, BioLegend Inc., R&D Systems Inc, American Gene Technologies International Inc, NSJ Bioreagents, Cytodyn Inc., Affinity Biosciences
What are the most influential trends expected to drive the cc chemokine receptor type 5 market forward?
Major companies operating in the CC chemokine receptor type 5 market are focused on developing new drugs, such as a CCR5 antagonist, to gain a competitive advantage. A CC chemokine receptor type 5 (CCR5) antagonist is a type of drug that blocks the CC chemokine receptor type 5 (CCR5) receptor on immune cells, preventing certain pathogens such as HIV from binding and entering these cells, thereby inhibiting infection and modulating immune responses. For instance, in February 2024, CytoDyn Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold on leronlimab. The company is now authorized to continue with its planned HIV clinical trial to investigate leronlimab’s impact on chronic inflammation. Leronlimab, a CCR5 antagonist (also known as PRO 140), shows promise for various therapeutic applications due to its potential to target multiple health conditions and is being investigated for various indications, including HIV and cancer.
What are the major regional insights for the cc chemokine receptor type 5 market, and which region holds the top position?
North America was the largest region in the CC chemokine receptor type 5 market in 2024. The regions covered in the CC chemokine receptor type 5 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The CC Chemokine Receptor Type 5 Market Report 2025 Offer?
The cc chemokine receptor type 5 market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
CC chemokine receptor type 5 (CCR5) refers to a protein located on the surface of white blood cells that plays a key role in the immune system by acting as a receptor for certain chemokines, which are signaling molecules that direct the movement of immune cells towards sites of inflammation or infection. It is involved in the pathogenesis of diseases such as HIV, where it serves as a co-receptor, allowing the virus to enter and infect host cells, making it a target for therapeutic interventions.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18290
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model